Page 61 - AN-3-3

Advanced Neurology HS-proteoglycans and brain function

24. Holmes B, Diamond MI. Prion-like properties of Tau 35. Eigenbrot C, Ganesan R, Kirchhofer D. Hepatocyte
protein: The importance of extracellular Tau as a therapeutic growth factor activator (HGFA): Molecular structure
target. J Biol Chem. 2014;289(29):19855-19861. and interactions with HGFA inhibitor-1 (HAI-1). FEBS J.
2010;277(10):2215-2222.
doi: 10.1074/jbc.R114.549295
doi: 10.1111/j.1742-4658.2010.07638.x
25. Valko M, Jomova K, Rhodes CJ, Kuča K, Musílek K. Redox-
and non-redox-metal-induced formation of free radicals and 36. Salameh MA, Robinson JL, Navaneetham D, et al. The
their role in human disease. Arch Toxicol. 2016;90(1):1-37. amyloid precursor protein/protease nexin 2 Kunitz inhibitor
domain is a highly specific substrate of mesotrypsin. J Biol
doi: 10.1007/s00204-015-1579-5
Chem. 2010;285(3):1939-1949.
26. Melrose J. The potential of flavonoids and flavonoid
metabolites in the treatment of neurodegenerative pathology doi: 10.1074/jbc.M109.057216
in disorders of cognitive decline. Antioxidants (Basel). 37. Dar NJ, Glazner GW. Deciphering the neuroprotective and
2023;12(3):663. neurogenic potential of soluble amyloid precursor protein
alpha (sAPPα). Cell Mol Life Sci. 2020;77(12):2315-2330.
doi: 10.3390/antiox12030663
doi: 10.1007/s00018-019-03404-x
27. Vargas J, Grudina C, Zurzolo C. The prion-like spreading of
α-synuclein: From in vitro to in vivo models of Parkinson’s 38. Zhang Z, Tian Y, Ye K. δ-secretase in neurodegenerative
disease. Ageing Res Rev. 2019;50:89-101. diseases: Mechanisms, regulators and therapeutic
opportunities. Transl Neurodegener. 2020;9:1.
doi: 10.1016/j.arr.2019.01.012
doi: 10.1186/s40035-019-0179-3
28. Zhu Y, Gandy L, Zhang F, et al. Heparan sulfate proteoglycans
in tauopathy. Biomolecules. 2022;12(12):1792. 39. Marr HS, Basalamah MA, Bouldin TW, Duncan AW,
Edgell CJ. Distribution of testican expression in human
doi: 10.3390/biom12121792
brain. Cell Tissue Res. 2000;302(2):139-144.
29. Nguyen DLB, Okolicsanyi RK, Haupt SLM. Heparan doi: 10.1007/s004410000277
sulfate proteoglycans: Mediators of cellular and molecular
Alzheimer’s disease pathogenic factors via tunnelling 40. Barrera-Ocampo A, Arlt S, Matschke J, et al. Amyloid-
nanotubes? Mol Cell Neurosci. 2024;129:103936. beta precursor protein modulates the sorting of testican-1
and contributes to its accumulation in brain tissue and
doi: 10.1016/j.mcn.2024.103936
cerebrospinal fluid from patients with Alzheimer disease.
30. Snow AD, Cummings JA, Lake T. The unifying hypothesis J Neuropathol Exp Neurol. 2016;75(9):903-916.
of Alzheimer’s disease: Heparan sulfate proteoglycans/ doi: 10.1093/jnen/nlw065
glycosaminoglycans are key as first hypothesized over
30 years ago. Front Aging Neurosci. 2021;13:710683. 41. Smith SM, Melrose J. A retrospective analysis of the cartilage
kunitz protease inhibitory proteins identifies these as
doi: 10.3389/fnagi.2021.710683
members of the inter-α-trypsin inhibitor superfamily with
31. Kim SY, Jin W, Sood A, et al. Characterization of heparin potential roles in the protection of the articulatory surface.
and severe acute respiratory syndrome-related coronavirus Int J Mol Sci. 2019;20(3):497.
2 (SARS-CoV-2) spike glycoprotein binding interactions. doi: 10.3390/ijms20030497
Antiviral Res. 2020;181:104873.
42. Qian Y, Yang L, Chen J, et al. SRGN amplifies microglia-
doi: 10.1016/j.antiviral.2020.104873
mediated neuroinflammation and exacerbates ischemic
32. Chen X, Nakada S, Donahue JE, et al. Neuroprotective effects brain injury. J Neuroinflammation. 2024;21(1):35.
of inter-alpha inhibitor proteins after hypoxic-ischemic doi: 10.1186/s12974-024-03026-6
brain injury in neonatal rats. Exp Neurol. 2019;317:244-259.
43. Liu P, Li HQ, Dong MQ, et al. Infiltrating myeloid
doi: 10.1016/j.expneurol.2019.03.013
cell-derived properdin markedly promotes microglia-
33. Takano M, Mori Y, Shiraki H, et al. Detection of mediated neuroinflammation after ischemic stroke.
bikunin mRNA in limited portions of rat brain. Life Sci. J Neuroinflammation. 2023;20(1):260.
1999;65(8):757-762.
doi: 10.1186/s12974-023-02946-z
doi: 10.1016/s0024-3205(99)00302-1
44. Michels MAH, Volokhina EB, van de Kar NCA, van
34. Maroney SA, Westrick RJ, Cleuren AC, et al. Tissue den Heuvel LPW. The role of properdin in complement-
factor pathway inhibitor is required for cerebrovascular mediated renal diseases: A new player in complement-
development in mice. Blood. 2021;137(2):258-268. inhibiting therapy? Pediatr Nephrol. 2019;34(8):1349-1367.
doi: 10.1182/blood.2020006054 doi: 10.1007/s00467-018-4042-z

Volume 3 Issue 3 (2024) 14 doi: 10.36922/an.3812